245 results about "Ocular disease" patented technology

The invention belongs to the technical field of nano-drugs, and discloses a multifunctional nano-drug delivery system for treating neovascular eye diseases and a preparation method of the multifunctional nano-drug delivery system. The nano drug delivery system disclosed by the invention is a composite nano preparation which takes dendritic mesoporous silica nanoparticles as a carrier and co-loads cerium zirconium oxide nano enzyme and an anti-VEGF (vascular endothelial growth factor) drug, various active oxygen can be efficiently removed, oxygen is continuously released through catalytic decomposition of hydrogen peroxide, a retina hypoxia microenvironment is improved, and the retina hypoxia effect is improved. According to the present invention, the anti-VEGF drug delivery system can reduce the oxidative stress induced retinal pigment epithelial cell apoptosis rate, reduce the inflammatory reaction, and simultaneously achieve the slow release and the controlled release of the anti-VEGF drug, and the drug effect maintenance time can achieve more than 60 days, such that the multi-target synergistic treatment can be achieved through the synergistic regulation of the multiple pathological links such as oxygen deficit-oxidative stress-inflammation-angiogenesis, and the anti-VEGF drug delivery effect can be achieved. The choroidal neovascularization can be effectively inhibited by single intravitreal injection, and a new strategy of multi-target collaborative treatment is provided for neovascular macular degeneration and other eye diseases.

The present invention is in the fields of medicinal chemistry, biotechnology and pharmaceuticals. The invention provides compositions comprising one or more collagen mimetic peptides, optionally attached to one or more therapeutic compounds or one or more imaging compounds, for use in methods of treating, preventing, ameliorating, curing and diagnosing certain diseases and physical disorders in humans and veterinary animals, as well as methods of manufacturing such composition. The invention also provides medical devices comprising one or more such compositions of the invention. The invention also provides methods of use of such compositions and devices in treating and diagnosing certain diseases and physical disorders in humans and veterinary animals, including ocular diseases or disorders, skin diseases or disorders, certain cancers, particularly intraluminal cancers, gastrointestinal diseases or disorders, genitourinary tract diseases or disorders, fibrotic diseases / disorders and rheumatic diseases / disorders.

The invention discloses a continuous optical zoom slit-lamp microscope system and an inspection method and application thereof, and belongs to the technical field of ophthalmology medical equipment. The system is composed of a continuous zooming module, a light source module, a data processing module, a 3D imaging module and an AI identification module. The inspection method comprises the steps of equipment initialization and head position fixation of an inspected person, AI low-magnification (5 *) preliminary screening, adaptive lens high-magnification (40 *) fine observation, dynamic light source adjustment, three-dimensional data acquisition and cloud intelligent diagnosis. The method is applied to examination and intelligent diagnosis of eye diseases such as cataract. The problems that a traditional slit-lamp microscope is discontinuous in zooming, inconvenient to operate, lack of intelligent diagnosis and free of 3D stereoscopic display are solved, and the objective of the invention is to realize simple and convenient equipment operation, continuous examination process, intelligent diagnosis and stereoscopic display, facilitate collective teaching, significantly improve the diagnosis efficiency and accuracy of eye diseases such as cataract and the like, and improve the diagnosis efficiency and accuracy of eye diseases such as cataract and the like. And DICOM standard data cloud sharing and remote consultation are supported.

The present invention relates to a protein tyrosine kinase inhibitor for the treatment of protein tyrosine kinase-mediated proliferative diseases or symptoms, for example ocular diseases including pathological neovascularization, retinal ischemia, retinal edema, and diabetic retinopathy, as well as malignant tumors. More particularly, the present invention relates to a compound with protein tyrosine kinase inhibitory activity and / or improved solubility and ocular bioavailability, and its uses in the treatment of ocular diseases and malignant tumors.

The present invention is in the field of ocular disease therapy. In particular, the invention relates to a composition comprising pimecrolimus for use in the topical treatment of moderate to severe blepharitis, in particular in a patient group comprising subjects with a clinical diagnosis of moderate to severe blepharitis, wherein the subjects to be treated have signs and symptoms of moderate to severe blepharitis characterised by swelling of the eyelid margin, ocular debris and ocular discomfort. In particular, the present invention relates to an ophthalmic composition that shows a high patient acceptance and a clinically meaningful improvement in the signs and symptoms of treated patients.

A composition includes an extract portion extracted from a plant selected from rosewood, myrtle, rosemary, and combinations thereof, and a carrier liquid portion. Uses of the compositions for ameliorating one or more ocular diseases and conditions are provided. Eye drop formulations containing the composition are provided.

Provided herein are screening methods and animal models relevant to ocular diseases such as age-related macular degeneration (AMD), e.g., for use in identifying candidate therapeutics for treating or preventing ocular diseases such as AMD. Also provided herein are compounds / compositions useful for killing or inhibiting the growth of microorganisms such as Bacillus megaterium. Further provided herein are methods of using the compounds / compositions to treat infections with microorganisms such as Bacillus megaterium, as well as to treat or prevent diseases or conditions associated with such infections, such as AMD.

An implant device for an eye disease to be inserted into an eyeball may include: a tube having one end to be inserted into an anterior chamber of the eyeball, the tube comprising a hollow portion through which aqueous humor is drained; and a ripcord inserted into the hollow portion of the tube to control an amount of aqueous humor drainage through the tube. In the implant device, an inner diameter of the tube and a diameter of the ripcord are determined so that pressure formed in the anterior chamber of the eyeball when the tube is inserted into the anterior chamber of the eyeball is within a preset pressure range. The pressure formed in an anterior chamber to an optimal range through an appropriate combination of the tube and the ripcord inserted into the tube.

In one aspect, the present application provides azabicyclo and diazepine derivatives useful as muscarinic receptor modulators. In another aspect, the present application provides pharmaceutical compositions for the treatment of ocular diseases, the compositions comprising at least one muscarinic receptor modulator. Formulas (I) and (II):

1. The name of the design product: science popularization interactive instrument (ocular disease simulation). 2. The use of the design product: for science popularization and interaction. 3. The design points of the design product: in shape. 4. The picture or photo that best indicates the design points: perspective view 1. 5. The right view, top view, and bottom view are omitted in the perspective view 1 and perspective view 2. The bottom surface of the design product is a part that is not easily visible or invisible during use, so the top view is omitted.

The invention relates to a product suitable for the treatment of tear film deficiency in dry eye disease and a method for manufacturing the product. The invention also relates to a product for use in the treatment of tear film deficiency in dry eye disease. The product according to the invention provides for an improved wound healing in dry eye disease and other pathologies.

The present application provides compositions and methods for treatment of ocular inflammatory conditions, dry eye diseases, and abnormal corneal neovascularization, using etiprednol. In one example, a composition is provided comprising a semi-fluorinated alkane compound such as, e.g., perfluorohexyloctane; and an additive selected from paraffin, propylene glycol diacetate (PGD), a hydroxyalkyl ester of an aliphatic fatty acid, a hydroxyacid alkyl ester, an alkyl ester of a fatty acid, phenethyl alcohol, ethanol, isopropanol, glycerol, propylene glycol, polyethylene glycol, n-butanol, or combinations thereof. Eye drops comprising the compositions are also provided. Methods of using the compositions are also provided and include methods for reducing one or more symptoms of ocular inflammatory conditions, dry eye diseases, or abnormal corneal neovascularization.

The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4 H-quinazolin-3-yl)-benzonitrile.

The invention relates to the technical field of medicine, in particular to an ophthalmology clinic system and method simulating a three-level diagnosis and treatment mode and medical device.The system comprises a triage module provided with a first diagnosis model and capable of achieving eye disease screening and early triage based on single-mode image data and clinical data of eyes of a user; the diagnosis module is provided with a data fusion model and a second diagnosis module and can realize accurate recognition and disease progress prediction of complex eye diseases, the decision module is provided with a third diagnosis model and can provide personalized eye disease treatment scheme suggestions for patients, and the patients are propagandized and educated in combination with a large language model, so that the diagnosis efficiency is improved. And the clinical decision-making efficiency and the self-management ability of the patient are improved. Therefore, the problems of limited screening capability, low accuracy, incapability of effectively predicting the development trend of diseases and the like due to the fact that ophthalmology diagnosis mostly depends on single image analysis in related technologies are solved.

Provided herein are solid forms, e.g., polymorphs, of 2-(3-((7R,8aS)-7-fluorohexahydropyrrolo[1,2-a]pyrazin-2(1H)-yl)-1-(5-methyl-2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)azetidin-3-yl)acetonitrile, which are useful for treating kinase-related diseases or disorders. The solid forms, and compositions thereof, are useful for treating diseases in a subject, including, but not limited to, ocular diseases such as glaucoma, ocular hypertension, ocular wound repair, neurodegenerative ocular diseases, retinal detachment, and non-ocular diseases such as nerve injury, or skin wound repair, or inflammatory diseases, among others. (Compound 1) TIFF2026501674000028.tif4839

Methods for treating ocular diseases such as dry age-related macular degeneration include administering non-invasive photobiomodulation light therapy in the context of a prior PBM treatment, on the basis of a subject response to prior PBM treatment, on the basis of a patient pre-treatment characteristic, and combinations thereof. In some embodiments, methods comprise administering PBM therapy to subjects who have received PBM about four to six months prior to the present administering. In some embodiments, methods comprise administering PBM therapy to subjects in early stages of dry age-related macular degeneration.

This invention provides a traditional Chinese medicine composition and its application in the preparation of a topical herbal eye patch for treating thyroid eye diseases, belonging to the field of biomedical technology. The herbal composition consists of *Gynostemma pentaphyllum*, peppermint, *Platycladus orientalis* leaves, borneol, cicada slough, *Astragalus membranaceus*, *Selaginella tamariscina*, *Pteris vittata*, *Scutellaria baicalensis*, apricot leaf, and *Ipomoea aquatica*. Using this herbal composition as raw material, a topical herbal eye patch is prepared. This patch acts directly on acupoints and skin around the eyes, allowing the medicinal properties to penetrate the skin and reach the eye system, achieving the effects of promoting blood circulation, clearing heat and detoxifying, invigorating qi and unblocking meridians, reducing swelling and improving vision. It is suitable for the treatment of thyroid-related eye diseases. This invention's topical herbal eye patch can effectively improve clinical symptoms such as exophthalmos and eye inflammation in patients with thyroid eye diseases, positively impacting their quality of life and effectively improving the clinical treatment efficacy of this disease. The topical herbal eye patch provided by this invention can be further promoted and applied in the clinical treatment of thyroid eye diseases.

The present application relates to (i) a variant adeno-associated virus (AAV) capsid polypeptide comprising a peptide insertion in the variable region IV or in the variable region VIII relative to a wild-type AAV capsid polypeptide, wherein the peptide insertion comprises an amino acid sequence selected from the group consisting of SEQ ID NOs:1-29 or an amino acid sequence having at least 70% sequence identity thereto, (ii) an isolated nucleic acid encoding the aforementioned variant polypeptide, (iii) a recombinant polynucleotide comprising the aforementioned nucleic acid, and (iv) an isolated cell comprising the aforementioned polypeptide, nucleic acid or recombinant polynucleotide. The present application further relates to (v) an adeno-associated virus (AAV) vector comprising the aforementioned variant polypeptide, (vi) a pharmaceutical composition comprising the aforementioned AAV vector as well as (vii) the use of the aforementioned vector or pharmaceutical composition in preventing or treating an ocular disease. Finally, the present application relates to (viii) a method of delivering a heterologous nucleic acid to a retinal cell and (ix) a method of delivering a heterologous nucleic acid to the eye of a subject.

The invention provides ophthalmic devices provided with improved blue filtering, mimicking the transmittance of the human ageing eye closer than hitherto possible. The invention furthermore provides methods to obtain such ophthalmic devices, as well as application thereof for prevention or treatment of a degenerative eye disease.

The invention provides antisense oligonucleotide aiming at a Sptbnl target spot and application of the antisense oligonucleotide. The antisense oligonucleotide can be used for knocking down the expression of Sptbnl, and in-vivo and in-vitro experiments find that the antisense oligonucleotide can be used for treating hyperlipidemia and NASH and can also be used for treating neovascular eye diseases.

The present disclosure relates to methods of preparing biodegradable ocular implants containing edonentan, or a pharmaceutically acceptable salt thereof. The disclosure also relates to biodegradable ocular implants generally comprising a biodegradable polymer and edonentan, or a pharmaceutically acceptable salt thereof.

The present invention relates to a crosslinkable liquid composition for use in a method of treating an eye disease of a subject eye, comprising (i) polyethylene glycol diacrylate (PEGDA), (ii) gelatin or a gelatin-based crosslinkable biomaterial, and (iii) a photoinitiator and optionally a coinitiator, the method comprising applying the crosslinkable liquid composition to the anterior corneal surface of the eye having the eye disease using a mold, crosslinking the crosslinkable liquid composition on the anterior corneal surface of the eye, thereby obtaining a composition crosslinked on the anterior corneal surface of the eye, and correcting the curvature of the crosslinked composition.

This invention relates to pharmaceutical compositions and methods for treatment of ophthalmic or ocular diseases and conditions. The compositions contain targeting molecules that are made up of a bifunctional hepatoma-derived growth factor-specific antibody covalently attached to a trapper that specifically binds vascular endothelial growth factor and / or transforming growth factor beta. Specific eye conditions that can be beneficially affected by the compositions and methods of the invention include age-related macular degeneration, diabetic retinopathy, peripheral vitreoretinopathy, and retinal vein occlusion.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

Disclosed herein is a system and method for treating dry eye disease / dry eye syndrome in a subject, the system including a controller and an energy signal generator. Further included is at least one energy applicator configured to receive the energy signal from the energy signal generator and to apply a first energy signal and a second energy signal different from the first energy signal to a periorbital region of the eye of the subject. Wherein the first energy signal is configured to heat meibomian glands of the eye to a predetermined temperature and the second energy signal is configured to heat collagenous fibers in the eye to a predetermined temperature.

The present invention provides methods for treating or preventing diabetic retinopathy. e.g., nonproliferative diabetic retinopathy, by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include administering 2 mg of aflibercept by intravitreal injection q8 weeks after three or five initial monthly doses (2q8) or 2 mg q16 weeks after three initial monthly doses and an 8-week interval (2q16). In addition. the present invention provides methods for reversing or halting the progression of NPDR to PDR (e.g., such that NPDR is reduced by 2 or 3 levels) or preventing the occurrence or recurrence of a vision-threatening complication by administering aflibercept according to the dosage regimens presented herein.

Disclosed herein are anti-Factor XIIa antibodies and methods of using such for treating diseases associated with Factor XII, including diseases associated with contact system activation, plasma prekallikrein signaling (e.g., hereditary angioedema), and ocular diseases.

Provided are a set of fully human TSH receptor (TSHR)-blocking monoclonal antibodies targeting a CHK36 homolog cluster, a preparation method therefor, and an application thereof. The method comprises the following steps: using flow cytometry to sort plasma cells and single memory B cells that specifically recognize TSHR in peripheral blood of a patient with a high titer of TSH-blocking antibodies (TBAb), performing in vitro cloning of antibody light and heavy chains and performing recombinant expression, and using hTSHR-CHO cells to perform screening and validation of antibody properties to obtain a blocking monoclonal antibody that specifically targets human TSHR. The fully human TSH receptor-blocking monoclonal antibodies specifically bind to a TSHR, and effectively block signal transduction after a TSH binds to a receptor, inhibit the synthetic secretion of thyroid hormones, and significantly reduce and inhibit TSHR expression and fibrosis in orbital fibroblasts of effector cells associated with thyroid-related ocular diseases. The fully human TSH receptor-blocking monoclonal antibodies have broad application prospects in the treatment of Graves' disease (GD) and other diseases caused by hyperthyroidism, such as thyroid eye disease (TED).

Methods and compositions for gene therapy of retinal degeneration related to mutations in MER proto-oncogene, tyrosine kinase (MERTK).